UNITED STATES PATENT AND TRADEMARK OFFICE
`
`———————
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`———————
`
`ETON PHARMACEUTICALS, INC.,
`
`Petitioner
`
`v.
`
`EXELA PHARMA SCIENCES, LLC,
`
`Patent Owner
`
`———————
`
`U.S. PATENT NO. 10,583,155
`
`PGR2020-00068
`
`PETITIONER'S UPDATED INDEX OF EXHIBITS
`
`
`
`———————
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`———————
`
`ETON PHARMACEUTICALS, INC.,
`
`Petitioner
`
`v.
`
`EXELA PHARMA SCIENCES, LLC,
`
`Patent Owner
`
`———————
`
`U.S. PATENT NO. 10,583,155
`
`PGR2020-00068
`
`PETITIONER'S UPDATED INDEX OF EXHIBITS
`
`
`
`PGR2020-00068: Petitioner’s Updated Index of Exhibits
`
`PETITIONER’S INDEX OF EXHIBITS
`
`Exhibit Description
`
`1001
`
`U.S. Patent No. 10,583,155 (“’155 patent”)
`
`1002
`
`U.S. Patent No. 10,478,453 File History
`
`1003
`
`Declaration of Barrett Rabinow, Ph.D.
`
`1004
`
`Affidavit of Christopher Butler
`
`1005
`
`Way Back Machine Screenshots of
`
`https://web.archive.org/web/20170403170533/http:/drugsdb.eu/drug.p
`hp?d=L-
`cysteine%20Hydrochloride&m=Sandoz%20Inc&id=083366d6-0437-
`4ee0-90d4-440a5b5d03b5.xml and
`
`https://web.archive.org/web/20160824090050/http:/drugsdb.eu/drug.p
`hp?d=L-
`cysteine%20Hydrochloride&m=Sandoz%20Inc&id=083366d6-0437-
`4ee0-90d4-440a5b5d03b5.xml
`
`1006
`
`1007
`
`1008
`
`A Hernández-Sánchez et al., Aluminum in Parenteral Nutrition: A
`Systematic Review, 67 EUR. J. CLINICAL NUTRITION 230 (2013)
`
`Robert L. Poole et al., Aluminum in Pediatric Parenteral Nutrition
`Products: Measured Versus Labeled Content, 16 J. PEDIATRIC
`PHARMACOLOGY & THERAPEUTICS 92 (2011)
`
`Denise Bohrer et al., Influence of the Glass Packing on the
`Contamination of Pharmaceutical Products by Aluminum. Part II:
`Amino Acids for Parenteral Nutrition, 15 J. TRACE ELEMENTS MED. &
`BIOLOGY 103 (2001) (“Bohrer II”)
`
`1
`
`
`
`PGR2020-00068: Petitioner’s Updated Index of Exhibits
`
`1009
`
`Way Back Machine Screenshots of
`
`https://web.archive.org/web/20130831172706/http:/www.drugsdb.eu/d
`rug.php?d=Aminosyn&m=Hospira,%20Inc.&id=2A72A8B8-A77C-
`49C6-3C8D-43B03672D802.xml
`
`1010
`
`Affidavit of Christopher Butler
`
`1011
`
`1012
`
`Kavita Pilaniya et al., Recent Trends in the Impurity Profile of
`Pharmaceuticals, 3 J. ADVANCED PHARMACEUTICAL TECH. & RES. 302
`(2010)
`
`Denise Bohrer et al., Influence of the Glass Packing on the
`Contamination of Pharmaceutical Products by Aluminum. Part III:
`Interaction Container-Chemicals During the Heating for Sterilisation,
`17 J. TRACE ELEMENTS MED. & BIOLOGY 107 (2003) (“Bohrer III”)
`
`1013
`
`Q3D ELEMENTAL IMPURITIES: GUIDANCE FOR INDUSTRY (Sept. 2015)
`
`1014
`
`1015
`
`1016
`
`1017
`
`1018
`
`Michael J Akers, Parenteral Preparations, in REMINGTON: THE
`SCIENCE AND PRACTICE OF PHARMACY 810 (David B. Troy et al. eds.,
`21st ed. 2006)
`
`Winston W.K. Koo et al., Aluminum in Parenteral Nutrition
`Solution— Sources and Possible Alternatives, 10 J. PARENTERAL &
`ENTERAL NUTRITION 591 (1986)
`
`Cysteine, DRUGBANK, https://www.drugbank.ca/drugs/DB00151 (last
`visited May 7, 2020)
`
`Barrett E. Rabinow et al., Plastic Packaging Materials, in
`REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY 1047 (David
`B. Troy et al. eds., 21st ed. 2006)
`
`FDA GUIDANCE FOR INDUSTRY Q8(R2) PHARMACEUTICAL
`DEVELOPMENT, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
`FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION
`
`
`
`2
`
`
`
`PGR2020-00068: Petitioner’s Updated Index of Exhibits
`
`AND RESEARCH (CDER) CENTER FOR BIOLOGICS EVALUATION AND
`RESEARCH (CBER) (Nov. 2009)
`
`1019
`
`1020
`
`1021
`
`August 4, 2017 Letter from Donna Griebel, M.D., Director of Division
`of Gastroenterology and Inborn Errors Products, CDER, to Patent
`Owner
`
`Loyd V. Allen, L-Cysteine Hydrochloride 50 mg/mL Injection, 36 U.S.
`PHARMACIST 41 (Sept. 20, 2011)
`
`ESSENTIALS OF PHARMACEUTICAL CHEMISTRY (Donald Cairns ed., 4th
`ed. 2012)
`
`1022
`
`Declaration of Harry “Warren” Johnson
`
`1023
`
`1024
`
`1025
`
`1026
`
`1027
`
`1028
`
`M.X. Sullivan et al., The Effect of Pyruvic Acid on the Estimation of
`Cystine and Cysteine, 122 J. BIOL. CHEM. 11 (1937)
`
`R.S. Asquith et al., The Photochemical Degradation of Cystine in
`Aqueous Solution in the Presence of Air, 184 BIOCHIMICA ET
`BIOPHYSICA ACTA (BBA) – GENERAL SUBJECTS 345 (1969)
`
`Soji Rokushika et al., Radiolysis of Cystine in Aqueous Solution by
`Gamma Irradiation, 7-2 J. RADIATION RES. 47 (1966)
`
`Ben H. Nicolet, Biochemistry by Analogy: The Sulfur of Cystine, 28 J.
`WASH. ACADS. SCI. 84 (1938)
`
`Kenneth C. Waterman et al., Stabilization of Pharmaceuticals to
`Oxidative Degradation, 7 PHARMACEUTICAL DEV. & TECH. 1 (2002).
`
`Henri J. R. Maget, Use of an Oxygen Extractor to Minimize Oxidation
`of Compounded Preparations, 3 INT’L J. PHARM. COMPOUNDING 493
`(1999)
`
`1029
`
`Alpaslan Yaman, Engineering Considerations in Sterile Powder
`Processes, in STERILE PHARMACEUTICAL PRODUCTS: PROCESS
`
`
`
`3
`
`
`
`PGR2020-00068: Petitioner’s Updated Index of Exhibits
`
`ENGINEERING APPLICATIONS 297 (Kenneth E. Avis ed. 1995)
`
`1030
`
`Copyright Registration Number for Alpaslan Yaman, Engineering
`Considerations in Sterile Powder Processes, in STERILE
`PHARMACEUTICAL PRODUCTS: PROCESS ENGINEERING APPLICATIONS
`297 (Kenneth E. Avis ed. 1995)
`
`1031
`
`1032
`
`1033
`
`1034
`
`1035
`
`1036
`
`1037
`
`1038
`
`Jalpa Patel et al., Stability Considerations for Biopharmaceuticals,
`Part 1: Overview of Protein and Peptide Degradation Pathways, 2011
`BIOPROCESS INT’L 20
`
`Henry L. Avallone et al., Food and Drug Administration Inspection
`and Licensing of Manufacturing Facilities, in DRUG BIOTECHNOLOGY
`REGULATION: SCIENTIFIC BASIS AND PRACTICES 322-23 (Yuan-yuan H.
`Chiu et al. eds. 1991)
`
`Gaozhong Zhu et al., Formulation of Protein- and Peptide-Based
`Parental Products, in PHARMACEUTICAL DOSAGE FORMS (Sandeep
`Nema et al. eds. 2010)
`
`Andrew Teasdale et al., Impurities in New Drug Substances and New
`Drug Products: ICH Q3A/B: Key Guidelines in the General Impurity
`Management Process, in ICH QUALITY GUIDELINES: AN
`IMPLEMENTATION GUIDE (Andrew Teasdale et al. eds. 2018)
`
`Aluminum in Large and Small Volume Parenterals Used in Total
`Parenteral Nutrition, 65 Fed. Reg. 4103 (Jan. 26, 2000) (codified at 21
`C.F.R. pt. 201)
`
`G.J. Schuringa et al., The Reaction of Combined Cystine of Wool with
`Sodium Bisulfite, 21 TEXTILE RES. J. 281 (1951)
`
`Lawrence X. Yu et al., Understanding Pharmaceutical Quality by
`Design, 16 AM. ASSOC. PHARM. SCIENTISTS J. 771 (2014
`
`Victoria Lima-Rogel et al., Aluminum Contamination in Parenteral
`Nutrition Admixtures for Low-Birth-Weight Preterm Infants in Mexico,
`
`
`
`4
`
`
`
`PGR2020-00068: Petitioner’s Updated Index of Exhibits
`
`1039
`
`1040
`
`1041
`
`40 J. PARENTERAL AND ENTERAL NUTRITION 1014 (2016).
`
`Ulrich Reichert et al., Metal Residue: How Much is Too Much?,
`PHARMA MANUFACTURING (Aug. 19, 2013)
`
`Diane L. Tribble et al., Hypercysteinemia and Delayed Sulfur
`Excretion in Cirrhotics After Oral Cysteine Loads, 50 Am. Soc.
`Clinical Nutrition 1401 (1989)
`
`David Connaughton, Argon or Nitrogen: Which is Best for Your
`Application?, PARKER (Sept. 15, 2016), http://blog.parker.com/argon-
`or-nitrogen-which-is-best-for-your-application
`
`1042
`
`Prescribing Information for Selenious Acid Injection (revised
`04/2019)
`
`1043
`
`July 10, 2019 Press Release regarding Selenious Acid Injection
`
`1044
`
`Prescribing Information for Zinc Sulfate Injection (revised 07/2019)
`
`1045
`
`1046
`
`UCSF CHILDREN’S HOSPITAL INTENSIVE CARE NURSERY HOUSE STAFF
`MANUAL (2004-2006)
`
`Reese H. Clark et al., Effects of Two Different Doses of Amino Acid
`Supplementation on Growth and Blood Amino Acid Levels in
`Premature Neonates Admitted to the Neonatal Intensive Care Unit: A
`Randomized, Controlled Trial, 129 PEDIATRICS 1286 (2007)
`
`1047
`
`E. Friedmann et al., CCLXV, Reactions of Pyruvic Acid with
`Thiolacetic Acid and Cysteine, 30 BIOCHEM. J. 1886 (1936)
`
`1048
`
`U.S. Patent No. 8,415,337 (“’337 patent”)
`
`1049
`
`Maaike A. Riedijk et al., Cysteine: A Conditionally Essential Amino
`Acid In Low-Birth-Weight Preterm Infants?, 86 AM. J. CLIN.
`NUTRITION 1120 (2007)
`
`
`
`5
`
`
`
`PGR2020-00068: Petitioner’s Updated Index of Exhibits
`
`1050
`
`1051
`
`A. D. Patrick, The Degradative Metabolism of L-Cysteine and L-
`Cystine In Vitro By Liver in Cystinosis, 83 BIOCHEM. J. 248 (1962)
`
`Soghier LM et al., CYSTEINE, CYSTINE OR N-ACETYLCYSTEINE
`SUPPLEMENTATION IN PARENTERALLY FED NEONATES (REVIEW),
`COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2010).
`
`1052
`
`Screenshot of https://www.rxlist.com/aminosyn-sulfite-free-drug.htm
`
`1053
`
`1054
`
`1055
`
`1056
`
`1057
`
`1058
`
`1059
`
`August 2017 Important Drug Warning Letter from Patent Owner to
`Health Care Provider
`
`Aluminum in Large and Small Volume Parenterals Used in Total
`Parenteral Nutrition, 63 Fed. Reg. 176 (Jan. 5, 1998) (codified at 21
`C.F.R. 201)
`
`W. Mihatsch, et al., ESPGHAN/ESPEN/ESPR/ESPEN Guidelines on
`Pediatric Parenteral Nutrition: Calcium, Phosphorus and Magnesium,
`37 CLINICAL NUTRITION (2018)
`
`Dayong Luo et al., Kinetics and Mechanism of the Reaction of
`Cysteine and Hydrogen Peroxide in Aqueous Solution, 94 J. PHARM.
`SCI. 304 (2005)
`
`CDER – NON-CLINICAL REVIEW(S), APP. NO. 210906ORIG1S000
`(signed 09/28/2018)
`
`Arika Hanaki, et al., Manometric Study of the Copper-Catalyzed
`Oxidation of Cysteine, 19 CHEM. PHARM. BULL. 1006 (1971)
`
`
`E. S. Guzman Barron, Thiol Groups of Biological Importance, in
`Advances in Enzymology and Related Subjects of Biochemistry 203-
`207 (F. F. Nord ed., 1951)
`
`1060
`
`Daniel Rudman et al., Hypotyrosinemia, Hypocystinemia, and Failure
`to Retain Nitrogen During Total Parenteral Nutrition of Cirrhotic
`
`
`
`6
`
`
`
`PGR2020-00068: Petitioner’s Updated Index of Exhibits
`
`Patients, 81 GASTROENTEROLOGY 1025 (1981)
`
`1061
`
`1062
`
`1063
`
`1064
`
`Len Okabe, Studies on the Solubility of Cystine Under Various
`Conditions, and On A New Method of Cystine Preparation, 8
`BIOCHEM. J. 441 (1927)
`
`QUALITY BY DESIGN (QBD) APPROACHES FOR ORALLY INHALED AND
`NASAL DRUG PRODUCTS (OINDPS) IN THE USA, RDD EUROPE (2007)
`
`Walter D. Block et al., Methionine, Cysteine, Cystine, and Taurine
`Interrelationships in Human Plasma, 22 AM. J. CLINICAL NUTRITION
`33 (1969)
`
`Mary Fewtrell et al., Symposium 2: Micronutrients Under the
`Microscope Aluminium Exposure From Parenteral Nutrition in
`Preterm Infants and Later Health Outcomes During Childhood and
`Adolescence, 70 PROCEEDINGS OF THE NUTRITION SOC. 299 (2011)
`
`1065
`
`Charles J. J. Fox, On the Coefficients of Absorption of Nitrogen and
`Oxygen in Distilled Water and Sea-Water and of Atmospheric
`Carbonic Acid in Sea-Water, 5 TRANS. FARAD. SOC., 68 (1909)
`
`1066
`
`STANDARD METHODS FOR THE EXAMINATION OF WATER AND SEWAGE,
`APHA (2d ed. 1915)
`
`1067
`
`U.S. Patent No. 6,382,442 (“’442 patent”)
`
`1068
`
`21 C.F.R. § 201.323
`
`1069
`
`1070
`
`Kasra Kasaraian et al., Developing an Injectable Formula Containing
`an Oxygen-Sensitive Drug: A Case Study of Danofloxacin Injectable, 4
`PHARM. DEV. & TECH. 475 (1999)
`
`Michael L. McHalsky, et al., Reduction of Aluminum Levels in
`Dialysis Fluids Through the Development and Use of Accurate and
`Sensitive Analytical Methodology, 41 J. PARENTERAL SCI. & TECH. 67
`
`
`
`7
`
`
`
`PGR2020-00068: Petitioner’s Updated Index of Exhibits
`
`(1987)
`
`1071
`
`Barrett E. Rabinow et al., Aluminum in Parenteral Products: Analysis,
`Reduction and Implications for Pediatric TPN, 43 J. PARENTERAL SCI.
`& TECH. (1989)
`
`1072
`
`George C. Whipple et al., Solubility of Oxygen in Sea Water, 33 J. AM.
`CHEM. SOC. 362 (1911)
`
`1073
`
`Orange Book Screenshot for Elcys
`
`1074
`
`DRUG FACTS AND COMPARISONS (2015)
`
`1075
`
`Copyright Registration Number for DRUG FACTS AND COMPARISONS
`(2015)
`
`1076
`
`USP 32/NF 18, The U.S. Pharmacopeial Convention (1995)
`
`1077
`
`Eton Pharmaceuticals, Inc.’s May 6, 2020 Answer and Affirmative
`Defenses to Complaint in Exela Pharma Sciences, LLC v. Eton
`Pharmaceuticals, Inc., No. 20-00365-MN (D. Del., filed March 16,
`2020)
`
`1078
`
`Declaration of Daniel Ingles
`
`1079
`
`1080
`
`SIGMA ALDRICH PRODUCT INFORMATION, L-CYSTEINE
`HYDROCHLORIDE MONOHYDRATE (05/06)
`
`R.C. Whiting et al., Effect of Headspace Oxygen Concentration on
`Growth and Toxin Production by Proteolytic Strains of Clostridium
`Botulinum, 55 J. FOOD PROTECTION 23 (1992)
`
`1081
`
`Farideh Jalilehvand et al., Lead(II) Complex Formation with L-
`Cysteine in Aqueous Solution, 54 INORG. CHEM. 2160 (2015)
`
`1082
`
`Ian B. Butler et al., Removal of Dissolved Oxygen From Water: A
`
`
`
`8
`
`
`
`PGR2020-00068: Petitioner’s Updated Index of Exhibits
`
`Comparison of Four Common Techniques, 41 TALANTA 211 (1994)
`
`1083
`
`U.S. Patent No. 10,583,155 File History
`
`1084
`
`1085
`
`1086
`
`1087
`
`1088
`
`1089
`
`1090
`
`1091
`
`Jay Mirtallo et. al., Safe Practices for Parenteral Nutrition, 28 J.
`PARENTERAL & ENTERAL NUTRITION S39 (2004)
`
`Michael C. Storm et al., Cysteine Supplementation Normalizes Plasma
`Taurine Concentrations in Low Birth Weight Premature Infants
`Requiring Parenteral Nutrition Support, 27 NUTRITION WEEK 2003
`ABSTRACTS S4
`
`Johannes B. van Goudoever et al., ESPGHAN/ESPEN/ESPR/CSPEN
`Guidelines on Pediatric Parenteral Nutrition: Amino Acids, 37
`CLINICAL NUTRITION 2315 (2018)
`
`Letter from Baxter Healthcare Corp. to Healthcare Professional, dated
`November 30, 2017
`
`Ekhard E. Zeigler, Parenteral Nutrition¸ in IOWA NEONATOLOGY
`HANDBOOK (2006)
`
`Patricia Worthington et al., When is Parenteral Nutrition
`Appropriate?, 41 J. PARENTERAL & ENTERAL NUTRITION 324 (2017)
`
`Emily Gasser et al., Parenteral Nutrition: Macronutrient Composition
`and Requirements, 27 SUPPORT LINE 6 (2005)
`
`Determination that Cysteine Hydrochloride Injection, USP, 7.25%,
`Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,
`75 Fed. Reg. 31,790 (June 4, 2010)
`
`1092
`
`May 8, 2018 Citizen Petition regarding Cysteine Hydrochloride
`Injection 5% and Attachments (including Hospira Package Insert)
`
`1093
`
`Declaration of Madan Chilakuri
`
`
`
`9
`
`
`
`PGR2020-00068: Petitioner’s Updated Index of Exhibits
`
`1094
`
`1095
`
`1096
`
`1097
`
`1098
`
`1099
`
`1100
`
`BENTLEY’S TEXTBOOK OF PHARMACEUTICALS: AN ADAPTATION
`(Sanjay K. Jain eds. et al., 2012)
`
`Michael H. Malloy et al., Total Parenteral Nutrition in Sick Preterm
`Infants: Effects of Cysteine Supplementation with Nitrogen Intakes of
`240 and 400 mg/kg/day, 3 J. PEDIATRIC GASTROENTEROLOGY &
`NUTRITION 239 (1984)
`
`Terhi Ahola et al., N-Acetylcysteine Does Not Prevent
`Bronchopulmonary Dysplasia in Immature Infants: A Randomized
`Control Trial, 143 J. PEDIATRICS 713 (2003)
`
`Stanley H. Zlotkin, et al., Cysteine Supplementation to Cysteine-free
`Intravenous Feeding Regimens in Newborn Infants, 34 AM. J.
`CLINICAL NUTRITION 914 (1981)
`
`GUIDANCE FOR INDUSTRY: E11 CLINICAL INVESTIGATION
`OF MEDICINAL PRODUCTS IN THE PEDIATRIC POPULATION
`(Dec. 2000)
`
`THE UNITED STATES PHARMACOPEIA – THE NATIONAL FORMULARY,
`(1985)
`
`Joseph Boullata, Nutrients and Associated Substances, in REMINGTON:
`THE SCIENCE AND PRACTICE OF PHARMACY 1688 (David B. Troy et al.
`eds., 21st ed. 2006)
`
`1101
`
`U.S. Patent No. 10,478,453 (“’453 patent”)
`
`1102
`
`1103
`
`Yakup Yesil et al., Evaluation of the Children with Acute
`Acetaminophen Overdose and Intravenous N-Acetylcysteine
`Treatment, 34 PAK J. MED. SCI. 590 (2018)
`
`WM Lee et al., Intravenous N-Acetylcysteine Improves Transplant-
`Free Survival in Early Stage Non-Acetaminophen Acute Liver Failure,
`137 GASTROENTEROLOGY 856 (2009)
`
`
`
`10
`
`
`
`PGR2020-00068: Petitioner’s Updated Index of Exhibits
`
`1104
`
`Shadi S. Yarandi et al., Amino Acid Composition in Parenteral
`Nutrition: What is the Evidence?, 14 CURRENT OPINION IN CLINICAL
`NUTRITION & METABOLIC CARE, 75 (2011)
`
`1105
`
`Declaration of Judy He
`
`1106
`
`1107
`
`1108
`
`1109
`
`1110
`
`1111
`
`1112
`
`1113
`
`1114
`
`Excerpt From the File History of Pending Application No. 16/746,028
`– As-Filed Claims (Jan. 17, 2020)
`
`Excerpt From the File History of Pending Application No. 16/773,641
`– As-Filed Claims (Jan. 27, 2020)
`
`Excerpt From the File History of Pending Application No. 16/746,028
`– Notice of Allowance (May 14, 2020)
`
`Excerpt From the File History of Pending Application No. 16/773,641
`– Notice of Allowance (April 30, 2020)
`
`Excerpt From the File History of Pending Application No. 16/746,028
`– Request for Continued Examination (May 28, 2020) and Information
`Disclosure Statement (June 11, 2020)
`
`Excerpt From the File History of Pending Application No. 16/773,641
`– Request for Continued Examination (June 2, 2020) and Information
`Disclosure Statement (June 11, 2020)
`
`Excerpt From the File History of Pending Application No. 16/746,028
`– Non-Final Rejection (July 23, 2020)
`
`Excerpt From the File History of Pending Application No. 16/773,641
`– Non-Final Rejection (July 23, 2020)
`
`Excerpt From the File History of Pending Application No. 16/746,028
`– Information Disclosure Statement (April 17, 2020)
`
`1115
`
`Excerpt From the File History of Pending Application No. 16/773,641
`
`
`
`11
`
`
`
`PGR2020-00068: Petitioner’s Updated Index of Exhibits
`
`– Information Disclosure Statement (April 17, 2020)
`
`1116
`
`Declaration of John Geissler, Exhibit 1, Response in Opposition to
`Plaintiff’s Motion for Preliminary Injunction, Exela Pharma Sciences,
`LLC v. Sandoz, Inc., No. 1:19-cv-318 (W.D.N.C., Dec. 6, 2019)
`
`1117
`
`U.S. Patent No. 4,385,086
`
`
`
`October 19, 2020
`
`
`
`
`
`Respectfully submitted,
`
`/s/ Ralph J. Gabric
`
`Ralph J. Gabric (Reg. No 34,167)
`HAYNES and BOONE LLP
`2323 Victory Ave. Suite 700
`Dallas, TX 75219
`Tel.: (312) 216-1620
`ralph.gabric.ipr@haynesboone.com
`
`Counsel for Petitioner
`
`
`
`
`
`
`
`
`12
`
`
`
`PGR2020-00068: Petitioner’s Updated Index of Exhibits
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. §§ 42.105 and 42.6, I certify I caused a true and correct
`
`copy of the forgoing Petitioner’s Updated Index of Exhibits and Exhibits 1106 -
`
`1117 on Patent Owner as detailed below.
`
`
`
`Date of service October 19, 2020
`
`Person served Dorothy P. Whelan
`PGR48751-0007PS1@fr.com
`
`Alana Mannige
`PTABInbound@fr.com
`
`
`
`/s/ Ralph J. Gabric
`Ralph J. Gabric (Reg. No 34,167)
`HAYNES AND BOONE LLP
`2323 Victory Ave. Suite 700
`Dallas, TX 75219
`Tel.: (312) 216-1620
`ralph.gabric.ipr@haynesboone.com
`
`Counsel for Petitioner
`
`
`
`
`
`13
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
